10x Genomics (NASDAQ:TXG) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of 10x Genomics (NASDAQ:TXG) from a buy rating to a hold rating in a report issued on Saturday morning.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, August 30th. Zacks Research downgraded shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 5th. Barclays reissued an “overweight” rating and set a $15.00 price objective (up previously from $13.00) on shares of 10x Genomics in a research note on Friday, August 8th. Morgan Stanley reduced their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 12th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the company a “hold” rating in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.65.

10x Genomics Price Performance

Shares of NASDAQ TXG opened at $13.35 on Friday. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $24.38. The company has a market capitalization of $1.66 billion, a PE ratio of -19.07 and a beta of 2.00. The firm’s 50-day moving average is $13.24 and its two-hundred day moving average is $10.83.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same quarter in the prior year, the firm earned ($0.32) earnings per share. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. 10x Genomics has set its Q3 2025 guidance at EPS. On average, analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. This represents a 6.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 9,348 shares of the stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the transaction, the chief executive officer owned 945,892 shares in the company, valued at $13,043,850.68. This trade represents a 0.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,149 shares of company stock worth $539,865 in the last ninety days. 10.03% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TXG. Allworth Financial LP boosted its stake in 10x Genomics by 150.4% during the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock valued at $26,000 after acquiring an additional 1,364 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after buying an additional 1,614 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of 10x Genomics in the 4th quarter worth about $32,000. Signaturefd LLC lifted its position in shares of 10x Genomics by 134.3% in the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after buying an additional 2,409 shares during the last quarter. Finally, Whittier Trust Co. bought a new position in shares of 10x Genomics in the 1st quarter worth about $41,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.